プロフィール詳細

プロジェクトを作成

★★★★★

☆☆☆☆☆

★★★★★

☆☆☆☆☆

Michael C.に依頼

United States

Biotechnologist with 10+ years experience in bioprocess improvement & method development and antibody drug conjugates

プロフィール概要

HPLC method development, FTIR, purification, antibody drug conjugates, isothermal titration calorimetry, GROMACS, SEC-MALLS, light scattering, resin porosity measurement

専門分野

• ☆ Inorganic Chemistry
• ☆ Zoology
• ☆ Animal Science
• ☆ Animal Biotechnology
• ☆ Molecular Biology
• ☆ Recombinant DNA
• ☆ Biotechnology & Bioengineering
• ☆ Microbial Biotechnology
• ☆ Industrial Biotechnology
• ☆ Drug Development
• ☆ Bioanalytical Testing
• ☆ Pharmaceutical Manufacturing
• ☆ Bioprocess Development
• ☆ Technical & Scientific Writing

サービス

• Research
• Consulting
• Data & AI
• Product Development

Research Feasibility Study, Technology Scouting, Fact Checking, Gap Analysis, Gray Literature Search, Systematic Literature Review

Consulting Scientific and Technical Consulting

Data & AI Statistical Analysis, Big Data Analytics

Product Development Formulation, Stability/Shelf Life Testing, Product Evaluation, Material Sourcing, Product Validation, Concept Development, Prototyping

職務経験

Scientists

Avitide, LLC

12月 2020 - 現在

Olympus Biotech

2011 - 8月 2013

Research Biologist

Glycofi Inc

8月 2004 - 12月 2010

Agilix Corp

2002 - 2004

Cornell University

1996 - 1997

学歴

PhD (Chemistry)

Dartmouth College

8月 2013 - 現在

M.S. (Cell Biology)

Yale University

7月 1997 - 8月 2002

A.B. (Biochemistry)

Cornell University

8月 1992 - 5月 1996

認定資格

• 認定資格の詳細は未入力です。

出版物

CONFERENCE POSTER

Michael Cukan(2020). KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created By a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity By Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab . Blood. 136. (Supplement 1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 9--10. American Society of Hematology

Michael Cukan(2020). 635 A novel site-directed chemical conjugation technology confers antitumor activity via native Fc receptor to plasma immunoglobulin by attaching tumor binders . Regular and young investigator award abstracts. {BMJ} Publishing Group Ltd

JOURNAL ARTICLE

Cukan, Michael C. and Hopkins, Daniel and Burnina, Irina and Button, Michelle and Giaccone, Erin and Houston-Cummings, Nga Rewa and Jiang, Youwei and Li, Fang and Mallem, Muralidhar and Mitchell, Teresa and et al.(2012). Binding of DC-SIGN to glycoproteins expressed in glycoengineered Pichia pastoris . Journal of Immunological Methods. 386. (1-2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 34-42. Elsevier

Zhang, Ningyan and Liu, Liming and Dan Dumitru, Calin and Cummings, Nga Rewa Houston and Cukan, Michael and Jiang, Youwei and Li, Yuan and Li, Fang and Mitchell, Teresa and Mallem, Muralidhar R. and et al.(2011). Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study . mAbs. 3. (3). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 289-298. Landes Bioscience

Jiang, Youwei and Li, Fang and Zha, Dongxing and Potgieter, Thomas I. and Mitchell, Teresa and Moore, Renée and Cukan, Michael and Houston-Cummings, Nga Rewa and Nylen, Adam and Drummond, James E. and et al.(2011). Purification process development of a recombinant monoclonal antibody expressed in glycoengineered Pichia pastoris . Protein Expression and Purification. 76. (1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 7-14. Elsevier

Jiang, Youwei and Li, Fang and Button, Michelle and Cukan, Michael and Moore, Renee and Sharkey, Nathan and Li, Huijuan(2010). A high-throughput purification of monoclonal antibodies from glycoengineered Pichia pastoris . Protein Expression and Purification. 74. (1). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 9-15. Elsevier

An, Zhiqiang and Forrest, Gail and Moore, Renee and Cukan, Michael and Haytko, Peter and Huang, Lingyi and Vitelli, Salvatore and Zhao, Jing Zhang and Lu, Ping and Hua, Jin and et al.(2009). IgG2m4, an engineered antibody isotype with reduced Fc function . mAbs. 1. (6). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 572-579. Landes Bioscience

Potgieter, Thomas I. and Cukan, Michael and Drummond, James E. and Houston-Cummings, Nga Rewa and Jiang, Youwei and Li, Fang and Lynaugh, Heather and Mallem, Muralidhar and McKelvey, Troy W. and Mitchell, Teresa and et al.(2009). Production of monoclonal antibodies by glycoengineered Pichia pastoris . Journal of Biotechnology. 139. (4). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 318-325. Elsevier

Choi, Byung-Kwon and Actor, Jeffrey K. and Rios, Sandra and d’Anjou, Marc and Stadheim, Terrance A. and Warburton, Shannon and Giaccone, Erin and Cukan, Michael and Li, Huijuan and Kull, Angela and et al.(2008). Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response . Glycoconjugate Journal. 25. (6). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 581-593. Springer-Verlag

Li, Huijuan and Sethuraman, Natarajan and Stadheim, Terrance A and Zha, Dongxing and Prinz, Bianka and Ballew, Nicole and Bobrowicz, Piotr and Choi, Byung-Kwon and Cook, W James and Cukan, Michael and et al.(2006). Optimization of humanized IgGs in glycoengineered Pichia pastoris . Nature Biotechnology. 24. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 210-215. Nature Publishing Group

OTHER

Gong, Bing and Cukan, Michael and Fisher, Richard and Li, Huijuan and Stadheim, Terrance A. and Gerngross, Tillman(2009). Characterization of N-Linked Glycosylation on Recombinant Glycoproteins Produced in Pichia pastoris Using ESI-MS and MALDI-TOF . 213-223Springer-Verlag